CHRS Earnings Date: Nov 9, 2026 (Estimated) — Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CHRS's next earnings date?
Coherus Oncology, Inc. (CHRS) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.21 on revenue of $16.0M.
How did CHRS do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Coherus Oncology, Inc. posted EPS of -$0.19 versus the -$0.25 estimate, a beat of 58.3%. Revenue was $14.3M against a $14.4M estimate. The stock's 1-day post-earnings move was -12.8%.
How much does CHRS stock move after earnings?
CHRS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.4% (up or down) in the day after earnings.
About Coherus Oncology, Inc.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.25 | -0.19 | -58.33% | $14.3M | ✅ Beat | -12.76% | -19.31% | -5.52% |
| 2026-05-11 | Q1 2026 | -0.27 | -0.25 | +7.41% | $12.3M | ✅ Beat | -12.31% | -23.59% | -30.26% |
| 2026-03-09 | Q4 2025 | -0.34 | -0.34 | +0.00% | $12.7M | ➖ Inline | +1.04% | -13.99% | -11.92% |
| 2025-11-06 | Q3 2025 | -0.32 | -0.33 | -3.12% | $11.6M | ❌ Miss | -10.07% | -15.44% | -14.09% |
| 2025-03-10 | Q4 2024 | -0.13 | -0.28 | -115.38% | $54.1M | ❌ Miss | +0.96% | -11.95% | -25.84% |
| 2024-11-06 | Q3 2024 | -0.12 | -0.01 | +91.67% | $70.8M | ✅ Beat | +13.29% | +7.58% | +134.87% |
| 2024-08-08 | Q2 2024 | -0.16 | -0.14 | +12.50% | $65.0M | ✅ Beat | +10.85% | +20.16% | +1.55% |
| 2024-03-13 | Q4 2023 | -0.12 | -0.62 | -416.67% | $91.5M | ❌ Miss | -5.65% | +7.83% | -3.04% |
Showing last 8 quarters.